Sign In
Buy FLDM
$1.83
+0 (+0%)
At Close: Jul 20, 2022
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
11:48am, Tuesday, 05'th Apr 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Theravance Announces Phase 3 Data For Ampreloxetine Showing Clear Benefit In Multiple System Atrophy P
Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.
09:31pm, Monday, 04'th Apr 2022 GlobeNewswire Inc.
New Trading Symbol (NASDAQ:LAB) Expected to be Effective April 6, 2022
Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.
05:31pm, Monday, 04'th Apr 2022
New Trading Symbol (NASDAQ:LAB) Expected to be Effective April 6, 2022
Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion
08:05pm, Friday, 01'st Apr 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM) today announced that its stockholders have voted to approve all of the proposals related to the pre
Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion
04:05pm, Friday, 01'st Apr 2022
SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM) today announced that its stockholders have voted to approve all of the proposals related to the previ
Fluidigm Announces Support Agreement with Caligan Partners Related to $250 Million Strategic Capital Infusion by Casdin Capital and Viking Global
01:29pm, Tuesday, 29'th Mar 2022 GlobeNewswire Inc.
Caligan Partners to Vote “FOR” Casdin and Viking Transaction and All Other Fluidigm Proposals at the Special Meeting to be Reconvened on April 1, 2022
Caligan Partners to Vote “FOR” Casdin and Viking Transaction and All Other Fluidigm Proposals at the Special Meeting to be Reconvened on April 1, 2022
Fluidigm Highlights the Strategic Capital Infusion by Casdin Capital and Viking Global as the Only Actionable Financing Solution
12:30pm, Monday, 28'th Mar 2022 GlobeNewswire Inc.
Company Urges ALL Stockholders to Vote “FOR” the Proposals at the Special Meeting
Fluidigm Highlights the Strategic Capital Infusion by Casdin Capital and Viking Global as the Only Actionable Financing Solution
08:30am, Monday, 28'th Mar 2022
Company Urges ALL Stockholders to Vote “FOR” the Proposals at the Special Meeting
Fluidigm Adjourns Special Meeting of Stockholders Until April 1, 2022
08:00pm, Friday, 25'th Mar 2022 GlobeNewswire Inc.
Provides Stockholders Additional Time to Consider $250 Million Strategic Capital Infusion from Casdin Capital and Viking Global Investors Provides Stockholders Additional Time to Consider $250 Millio
Fluidigm Adjourns Special Meeting of Stockholders Until April 1, 2022
04:00pm, Friday, 25'th Mar 2022
Provides Stockholders Additional Time to Consider $250 Million Strategic Capital Infusion from Casdin Capital and Viking Global Investors Provides Stockholders Additional Time to Consider $250 Millio
Fluidigm Urges Stockholders to Vote “FOR” ALL Proposals Related to $250 Million Strategic Capital Infusion TODAY
08:00am, Monday, 21'st Mar 2022
Cash Investment Expected to Significantly Advance Fluidigm's Mission through New Growth Initiatives and Cost Structure Optimization Cash Investment Expected to Significantly Advance Fluidigm's Mission
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Fluidigm Stockholders Vote “FOR” ALL Proposals Related to $250 Million Strategic Capital Infusion
09:58pm, Thursday, 17'th Mar 2022 GlobeNewswire Inc.
Fluidigm Board of Directors Unanimously Recommends Stockholders Vote “FOR” ALL Proposals TODAY Fluidigm Board of Directors Unanimously Recommends Stockholders Vote “FOR” ALL Proposals TODAY
Fluidigm Board of Directors Unanimously Recommends Stockholders Vote “FOR” ALL Proposals TODAY Fluidigm Board of Directors Unanimously Recommends Stockholders Vote “FOR” ALL Proposals TODAY
Digital PCR (dPCR) and Real-Time PCR (qPCR) Market Worth USD 1180.1 million, Globally, by 2028 at 6.8% CAGR - Exclusive Report by Absolute Reports
06:37am, Friday, 18'th Feb 2022 Benzinga
Pune, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Global Digital PCR (dPCR) and Real-Time PCR (qPCR) Market report delivers a complete overview of key components like drivers, limitations, historic and current trends, technical development, and future growth. Research report contains company analysis, size, share, revenue and sales of the company, current advancements. Digital PCR and Real-Time PCR market analysis also focuses on the global key top industry players in the market, with details such as company profiles, capacity, production, price, cost, revenue. Get a Sample Copy of the Report at - https://www.absolutereports.com/enquiry/request-sample/20190575 The global Digital PCR and Real-Time PCR market size is projected to reach USD 1879.8 million by 2028, from USD 1180.1 million in 2021, at a CAGR of 6.8% during 2022-2028. Polymerase chain reaction (PCR) is a laboratory technique performed commonly to amplify DNA, thereby producing many copies of a particular section of DNA in interest.
